RELEVANCE: SARS-CoV-2 is the virus that causes the disease called COVID-19, short for “Coronavirus Disease of 2019”. Finding an effective vaccine for COVID-19 is one of several steps being taken to end this global pandemic.

DESCRIPTION: The purpose of this study is to test Moderna’s vaccine candidate (mRNA-1273) to see if it can prevent illness if people are exposed to the SARS-CoV-2 virus in their everyday lives. This vaccine is not made from the SARS-CoV-2 virus. It is made from messenger ribonucleic acid (mRNA), a genetic code that tells cells how to make protein, which helps the body’s immune system make antibodies that can fight the virus. The vaccine cannot cause COVID-19 infection. This Phase 3 trial is being conducted at multiple clinic sites across the U.S. with a goal of enrolling 30,000 patients. Trial participants will receive 2 injections, approximately 28 days apart and will complete regular follow ups over the course of two years via phone calls, on-line surveys and additional in-person visits.

STATUS: This study is currently enrolling. Please call 323-461-3106 for more information or to be prescreened for the trial.